Doszklistkowe iniekcje ranibizumabu w terapii cukrzycowego obrzęku plamki

• Authors: Agata Prokopiuk , Anna Zubilewicz , Małgorzata Latalska , Jerzy Mackiewicz

Title variants

EN

Intravitreal ranibizumab injections as a treatment of diabetic macular edema

• Languages of publication: PL

Abstracts

PL

Cukrzycowy obrzęk plamki jest główną przyczyną pogorszenia widzenia u chorych na cukrzycę. Jego patogeneza wydaje się wieloczynnikowa. Obecnie zastosowanie w jego leczeniu znajdują m.in.: laseroterapia, doszklistkowa terapia anty-VEGF oraz glikokortykosteroidoterapia. W niniejszej pracy przedstawiono najnowsze wyniki badań dotyczących skuteczności doszklistkowych iniekcji ranibizumabu jako terapii, która zrewolucjonizowała leczenie cukrzycowego obrzęku plamki.

EN

Diabetic macular edema is a main cause of visual impairment in diabetic patients. Its pathogenesis seems to be multifactorial. Several therapeutic options have been accepted for the treatment of this disease. In this publication we present the newest results of efficacy of intravitreal ranibizumab therapy, as a one, that have revolutionised diabetic macular edema management.

Keywords

EN

cukrzycowy obrzęk plamki; ranibizumab; terapia anty-VEGF

Discipline

• MEDICINE: MEDICINE

• Publisher: Medical Education
• Journal: OphthaTherapy
• Year: 2015
• Volume: 2
• Issue: 4
• Pages: 272-276

Contributors

author

Agata Prokopiuk

• Katedra i Klinika Okulistyki, Uniwersytet Medyczny w Lublinie

author

Anna Zubilewicz

• Katedra i Klinika Okulistyki, Uniwersytet Medyczny w Lublinie

author

Małgorzata Latalska

• Katedra i Klinika Okulistyki, Uniwersytet Medyczny w Lublinie

author

Jerzy Mackiewicz

• Katedra i Klinika Okulistyki, Uniwersytet Medyczny w Lublinie

References

• 1. Mitchell P, Yin Wong T. Perspective management paradigms for diabetic macular edema. Am J Ophthalmol 2014; 157(3): 505- -513.
• 2. Zasady postępowania w cukrzycowym obrzęku plamki. Wytyczne Polskiego Towarzystwa Okulistycznego 2014.
• 3. Rotsos TG, Moschos MM. Cystoid macular edema. Journal of Clinical Ophthalmology 2008; 2(4): 919-930.
• 4. Bhagat N, Grigorian RA, Tutela A, Zarbin MA. Diabetic macular edema: pathogenesis and treatment. Survey of Ophthalmology 2009; 54(1): 1-32.
• 5. Early Treatment Diabetic Retinopathy Study Research Group. Photocoagulation for diabetic macular edema. EDTRS report number 1. Arch Ophthalmol 1985; 103(12): 1796-1806.
• 6. Schmidt-Erfurth U, Lang GE, Holz FG, et al.; RESTORE Extension Study Group. Three-year outcomes of individualized ranibizumab treatment in patients with diabetic macular edema: the RESTORE extension study. Ophthalmology 2014; 121(5): 1045-1053.
• 7. Zhang Y, Yao Z, Kaila N, et al. Pharmacokinetics of Ranibizumab after Intravitreal Administration in Patients with Retinal Vein Occlusion or Diabetic Macular Edema. Ophthalmology 2014; 121(11): 2237-2246.
• 8. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011; 118(4): 609-614.
• 9. Nguyen QD, Brown DM, Marcus DM, et al; on behalf of the RISE and RIDE Research Group. Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE. Ophthalmology 2012; 119(4): 789-801.
• 10. Brown DM, Nguyen QD, Marcus DM, et al; on behalf of the RIDE and RISE Research Group. Long-term outcomes of ranibizumab therapy for diabetic macular edema: the 36-month results from two phase III trials: RISE and RIDE. Ophthalmology 2013; 120(10): 2013-2022.
• 11. Nguyen QD, Shah SM, Khwaja AA, et al.; READ-2 Study Group. Two-year outcomes of the ranibizumab for edema of the mAcula in Diabetes (READ-2) study. Ophthalmology 2010; 117(11): 2146-2151.
• 12. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010; 33(11): 2399-2405.
• 13. Mitchell P, Bandello F, Schmidt-Erfurth U, et al; on behalf of the RESTORE Study Group. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011; 118: 615-625.
• 14. Domalpally A, Ip MS, Ehrlich JS. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Ophthalmology 2015; 122(4): 779-786.
• 15. Boyer DS, Nguyen QD, Brown DM, et al; RIDE and RISE Research Group Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials. Ophthalmology 2015 Oct 6. pii: S0161- -6420(15)00783-6.
• 16. Pearce I, Banerjee S, Burton BJ, et al.; RELIGHT Study Group. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study. Ophthalmology 2015; 122(9): 1811-1819.
• 17. Sadiq MA, Soliman MK, Sarwar S, et al; READ-3 Study Group. Effect of Vitreomacular Adhesion on Treatment Outcomes in the Ranibizumab for Edema of the Macula in Diabetes (READ-3) Study. Ophthalmology 2015 Oct 28. pii: S0161-6420(15)01110-0 [epub ahead of print].
• 18. Ishibashi T, Li X, Koh A, et al.; REVEAL Study Group. The REVEAL Study: Ranibizumab Monotherapy or Combined with Laser versus Laser Monotherapy in Asian Patients with Diabetic Macular Edema. Ophthalmology 2015; 122(7): 1402-1415.

• Document Type: article